SAS Output

26-APR-2018 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9383 327 0 0 0 0 BREAST
        9383 327 0 0 0 0  
 
  2 Y 2 Chemo and Endocrine Therapy 2547 122 0 0 0 0  
      3 Endocrine Therapy Alone 2536 121 0 0 0 0  
        5083 243 0 0 0 0  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 785 185 93 49 18 2 BREAST
      2 Blinded drug + Endocrine 791 198 90 44 16 1  
        1576 383 183 93 34 3  
 
S1316-Compar. Effectiv. Trial for MBO 1 T 1 Randomization Surgery 5 4 2 1 0 0 SURV
      2 Randomization Non-surgical M 5 5 4 0 0 0  
      3 Patient Choice Surgery 45 22 9 8 1 0  
      4 Patient Choice Non-surgical M 100 49 22 12 2 0  
        155 80 37 21 3 0  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 454 288 123 65 24 7 CCD
      2 Site randomized: Control 307 251 108 45 15 1  
      3 SiteRand Int Risk: CSF 525 446 259 127 41 5  
      4 SiteRand Int Risk: No CSF 395 358 189 112 52 7  
        1681 1343 679 349 132 20  
 
S1417CD-Colorectal, Cost Cohort Study 1 Y 1 Observation 232 191 110 67 23 2 CCD
        232 191 110 67 23 2  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 205 187 112 62 15 4 BREAST
        205 187 112 62 15 4  
 
  2 Y 2 Observation 92 88 53 30 14 0  
      3 MK-3475 (Pembrolizumab) 86 80 46 28 6 0  
        178 168 99 58 20 0  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 6 6 6 2 0 0 SURV
        6 6 6 2 0 0  
 
  2 Y 1 Carvedilol 2 2 2 1 0 0  
      2 No intervention 3 3 3 2 1 0  
      3 Observation 1 1 1 0 0 0  
        6 6 6 3 1 0  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 32 29 17 9 3 0 GU
      2 Tokyo-172 BCG 31 29 17 10 5 1  
      3 Prime + Tokyo-172 BCG 29 28 15 8 3 0  
        92 86 49 27 11 1  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 489 147 78 24 14 0 PREV
        489 147 78 24 14 0  
 
  1 Y 1 Blinded drug 59 23 14 9 3 0  
      2 Blinded drug 36 0 0 0 0 0  
      3 Blinded drug 35 0 0 0 0 0  
      4 Blinded drug 62 27 14 5 2 0  
        192 50 28 14 5 0